{"drugs":["Afluria","Fluarix","Flucelvax","Flulaval","Fluvirin","Fluzone","Fluzone High-Dose","Fluzone Pediatric","Influenza Virus Vaccine (Subvirion)"],"mono":{"0":{"id":"300170-s-0","title":"Generic Names","mono":"Influenza Virus Vaccine (Subvirion)"},"1":{"id":"300170-s-1","title":"Dosing and Indications","sub":[{"id":"300170-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Influenza; Prophylaxis:<\/b> Administer 1 dose (0.5 mL) IM annually<\/li><li><b>Influenza; Prophylaxis:<\/b> (18 through 64 years) Administer 1 dose (0.1 mL) INTRADERMALLY annually<\/li><li><b>Influenza; Prophylaxis:<\/b> (65 years or older; Fluzone(R) High-Dose) Administer 1 dose (0.5 mL) IM annually<\/li><\/ul>"},{"id":"300170-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Usual dose:<\/b> Administer 1 or 2 doses IM based on age and vaccine history; minimum age for vaccination is 6 months<\/li><li><b>Influenza; Prophylaxis:<\/b> (9 years or older; Fluarix(R), Fluarix(R) Quadrivalent, Flulaval(R), Flulaval(R) Quadrivalent, Fluvarin(R), Fluzone(R), Fluzone(R) Quadrivalent) administer 1 dose (0.5 mL) IM annually<\/li><li><b>Influenza; Prophylaxis:<\/b> (6 to 35 months; Fluzone(R), Fluzone(R) Quadrivalent) administer 1 dose (0.25 mL) IM or 2 doses (0.25 mL each) IM separated by at least 4 weeks, depending on vaccination history<\/li><li><b>Influenza; Prophylaxis:<\/b> (3 to 8 years; Fluarix(R), Fluarix(R) Quadrivalent, Flulaval(R), Flulaval(R) Quadrivalent, Fluzone(R), Fluzone(R) Quadrivalent) administer 1 dose (0.5 mL) IM or 2 doses (0.5 mL each) IM separated by at least 4 weeks, depending on vaccination history<\/li><li><b>Influenza; Prophylaxis:<\/b> (4 to 8 years; Fluvirin(R)) administer 1 dose (0.5 mL) IM or 2 doses (0.5 mL each) IM separated by at least 4 weeks, depending on vaccination history<\/li><li><b>Influenza; Prophylaxis:<\/b> (5 to 8 years; Afluria(R)) administer 1 dose (0.5 mL) IM or 2 doses (0.5 mL) IM separated by at least 4 weeks if vaccination status unknown, vaccine-naive, or lacking vaccination with H1N1 antigen (ie, did not receive 2 or more doses since 2010 season); avoid use in children younger than 9 years due to the potential for fever or febrile seizures<\/li><\/ul>"},{"id":"300170-s-1-6","title":"Dose Adjustments","mono":"<b>Renal impairment, renal failure, ESRD, or hemodialysis-dependent:<\/b> No dose adjustment required "},{"id":"300170-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Influenza; Prophylaxis<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Exacerbation of asthma; Prophylaxis<\/li><li>Otitis media; Prophylaxis<\/li><\/ul>"}]},"3":{"id":"300170-s-3","title":"Contraindications\/Warnings","sub":[{"id":"300170-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to neomycin (Afluria(R), Agriflu(R)), kanamycin (Agriflu(R)), or polymyxin (Afluria(R))<\/li><li>previous severe allergic reaction to vaccine or to any component of the vaccine, including egg proteins<\/li><\/ul>"},{"id":"300170-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- syncope may occur, possibly accompanied by transient neurological signs (eg, visual disturbance, paresthesia, tonic-clonic limb movements), may occur<\/li><li>Hematologic:<\/li><li>-- patients with bleeding disorders (eg, hemophilia) or those receiving anticoagulant therapy have an increased risk of hematoma<\/li><li>Immunologic:<\/li><li>-- allergic reaction may occur in latex-sensitive individuals, as tip caps contain natural rubber latex<\/li><li>-- refer patients with hypersensitivity to egg protein to allergy specialist and perform risk assessment; monitoring recommended<\/li><li>-- immune response to vaccination may be lower in immunosuppressed patients, including those receiving immunosuppressive therapy<\/li><li>Neurologic:<\/li><li>-- consider risk vs benefit of administration if Guillain-Barre syndrome occurred within 6 weeks of previous vaccination<\/li><li>Other:<\/li><li>-- defer vaccination in patients with moderate to severe acute illness, with or without fever, unless the benefit outweighs the risk<\/li><li>-- increased risk of fever and febrile seizure in children (mostly younger than 5 years of age); use not recommended in children 6 months to 8 years of age; may use in patients aged 5 to 8 years with a condition that increases the risk of influenza complications only if no other vaccine is available<\/li><\/ul>"},{"id":"300170-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"300170-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Compatible with breastfeeding.<\/li><li>Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"300170-s-4","title":"Drug Interactions","sub":{"1":{"id":"300170-s-4-14","title":"Major","mono":"<ul><li>Cyclosporine (theoretical)<\/li><li>Warfarin (probable)<\/li><\/ul>"},"2":{"id":"300170-s-4-15","title":"Moderate","mono":"<ul><li>Carbamazepine (probable)<\/li><li>Rituximab (probable)<\/li><\/ul>"}}},"5":{"id":"300170-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (Adult, up to 76.4%; pediatric, up to 46%), Injection site induration (Adult, up to 58.4%; pediatric, up to 16.6%), Injection site mass (2% to 11%), Injection site pain (Adult, up to 64%; pediatric, up to 62%), Red color (adult, 10% to 23%; pediatric, 18% to 23%), Swelling at injection site (Adult, up to 56.8%; pediatric, up to 27%), Tenderness (adult, 34% to 60%; pediatric, 47.3% to 56.3%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (adult, 1% or greater; pediatric, 2.5% to 15%), Loss of appetite (pediatric, 5% to 24%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (adult, 0.3% to 18%; pediatric, 6%), Myalgia (Adult, up to 34.1%; pediatric, up to 29%)<\/li><li><b>Neurologic:<\/b>Headache (Adult, up to 33%; pediatric, up to 16.7%), Somnolence (Pediatric, 13% to 26.7%)<\/li><li><b>Psychiatric:<\/b>Irritability (pediatric, 0.7% to 48%)<\/li><li><b>Other:<\/b>Fatigue (adult, up to 21%; pediatric, 20%), Fever (Adult, less than 1% to 11%; pediatric, up to 37%), Malaise (Adult, 1% to 27.7%; pediatric, 14.6% to 20%), Shivering (Adult, 1% to 12.4%; pediatric, 3%)<\/li><\/ul><b>Serious<\/b><br\/><b>Immunologic:<\/b>Hypersensitivity reaction<br\/>"},"6":{"id":"300170-s-6","title":"Drug Name Info","sub":{"0":{"id":"300170-s-6-17","title":"US Trade Names","mono":"<ul><li>Fluvirin<\/li><li>Fluzone<\/li><li>Fluzone Pediatric<\/li><li>Fluarix<\/li><li>Flulaval<\/li><li>Afluria<\/li><li>Fluzone High-Dose<\/li><li>Flucelvax<\/li><\/ul>"},"2":{"id":"300170-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"300170-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"300170-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"9":{"id":"300170-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>Do not inject IV<br\/><\/li><li><b>Intradermal<\/b><br\/><ul><li>(Fluzone(R) intradermal, Fluzone(R) intradermal quadrivalent) gently shake injection system gently before use<\/li><li>(Fluzone(R) intradermal, Fluzone(R) intradermal quadrivalent) administer intradermally in the region of the deltoid muscle<\/li><\/ul><\/li><li><b>Intramuscular<\/b><br\/><ul><li>Shake well before use<\/li><li>If using a multidose vial, draw up each dose using a separate sterile needle and syringe<\/li><li>Use different injection sites if concomitant use of other vaccines is required<\/li><li>Preferred injection site in children, 6 to 35 months, is the anterolateral aspect of the thigh<\/li><li>Preferred injection site in adults and older children is the deltoid muscle<\/li><li>Do not administer in the gluteal area or areas where there may be a major nerve trunk<\/li><\/ul><\/li><\/ul>"},"10":{"id":"300170-s-10","title":"Monitoring","mono":"no specific monitoring has been determined<br\/>"},"11":{"id":"300170-s-11","title":"How Supplied","mono":"<ul><li><b>Afluria 2013-2014 Formula<\/b><br\/>Intramuscular Suspension: 45 MCG\/0.5 ML<br\/><\/li><li><b>Afluria 2014-2015 Formula<\/b><br\/>Intramuscular Suspension: 45 MCG\/0.5 ML<br\/><\/li><li><b>Afluria<\/b><br\/>Intramuscular Suspension: 45 MCG\/0.5 ML<br\/><\/li><li><b>Fluarix 2014-2015 Formula<\/b><br\/>Intramuscular Suspension: 45 MCG\/0.5 ML<br\/><\/li><li><b>Fluarix Quadrivalent 2013-2014 Formula<\/b><br\/>Intramuscular Suspension: 60 MCG\/0.5 ML<br\/><\/li><li><b>Fluarix Quadrivalent 2014-2015 Formula<\/b><br\/>Intramuscular Suspension: 60 MCG\/0.5 ML<br\/><\/li><li><b>Flucelvax 2013-2014 Formula<\/b><br\/>Intramuscular Suspension: 45 MCG\/0.5 ML<br\/><\/li><li><b>Flucelvax 2014-2015 Formula<\/b><br\/>Intramuscular Suspension: 45 MCG\/0.5 ML<br\/><\/li><li><b>Flucelvax<\/b><br\/>Intramuscular Suspension: 45 MCG\/0.5 ML<br\/><\/li><li><b>Flulaval 2013-2014 Formula<\/b><br\/>Intramuscular Suspension: 45 MCG\/0.5 ML<br\/><\/li><li><b>FluLaval 2014-2015 Formula<\/b><br\/>Intramuscular Suspension: 45 MCG\/0.5 ML<br\/><\/li><li><b>Flulaval<\/b><br\/>Intramuscular Solution: 45 MCG\/0.5 ML<br\/><\/li><li><b>Flulaval Quadrivalent 2013-2014 Season<\/b><br\/>Intramuscular Suspension: 60 MCG\/0.5 ML<br\/><\/li><li><b>FluLaval Quadrivalent 2014-2015 Formula<\/b><br\/>Intramuscular Suspension: 60 MCG\/0.5 ML<br\/><\/li><li><b>Fluvirin 2013-2014 Formulation<\/b><br\/>Intramuscular Suspension: 45 MCG\/0.5 ML<br\/><\/li><li><b>Fluvirin 2014-2015 Formula<\/b><br\/>Intramuscular Suspension: 45 MCG\/0.5 ML<br\/><\/li><li><b>Fluvirin<\/b><br\/>Intramuscular Solution: 45 MCG\/0.5 ML<br\/><\/li><li><b>Fluzone 2014-2015 Formula<\/b><br\/><ul><li>Intradermal Suspension: 27 MCG\/0.1 ML<\/li><li>Intramuscular Suspension: 45 MCG\/0.5 ML<\/li><\/ul><\/li><li><b>Fluzone High-Dose 2014-2015 Formula<\/b><br\/>Intramuscular Suspension: 180 MCG\/0.5 ML<br\/><\/li><li><b>Fluzone Intradermal Quadrivalent 2014-2015 Formula<\/b><br\/>Intradermal Suspension: 36 MCG\/0.1 ML<br\/><\/li><li><b>Fluzone<\/b><br\/><ul><li>Intramuscular Solution: 45 MCG\/0.5 ML<\/li><li>Intramuscular Suspension: 45 MCG\/0.5 ML, 22.5 MCG\/0.25 ML<\/li><\/ul><\/li><\/ul>"},"13":{"id":"300170-s-13","title":"Clinical Teaching","mono":"<ul><li>Warn patient that influenza infection may still occur after vaccine, but symptoms should be less severe. Vaccine does not prevent other respiratory infections.<\/li><li>Drug may cause myalgia, fever, fatigue, headaches, malaise, diarrhea, vomiting, and injection-site reactions.<\/li><li>Instruct patient to immediately report signs\/symptoms of Guillain-Barr  syndrome (eg, myalgia, ataxia, muscle weakness, or paresthesias).<\/li><li>Advise patient to report severe or unusual adverse reactions following vaccination.<\/li><\/ul>"}}}